FDA Approves Eli Lilly’s Expensive Alzheimer’s Med

CNBC reports:

The Food and Drug Administration on Tuesday approved Eli Lilly’s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S. The agency approved the treatment, which will be sold under the brand name Kisunla.

Eli Lilly’s drug slowed Alzheimer’s progression by 35% over 18 months compared with a placebo, according to a late-stage trial.

The drug, which is administered through monthly infusions, will cost an estimated $12,522 for a six-month course, $32,000 for 12 months and $48,696 for 18 months. Medicare coverage and reimbursement is available for eligible patients, Eli Lilly said.

Read the full article.

Breaking news: The Food and Drug Administration on Tuesday granted approval to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing progression of the devastating disease outweigh its risks, drugmaker Eli Lilly announced. https://t.co/2cCuNXwewU

— The Washington Post (@washingtonpost) July 2, 2024

Breaking News: The @FDA approved a new amyloid-targeting therapy to treat adults with early symptomatic #AlzheimersDisease. Learn more: https://t.co/la14S3cUCz pic.twitter.com/KKhBVw49aZ

— Eli Lilly and Company (@EliLillyandCo) July 2, 2024